Provided by Tiger Fintech (Singapore) Pte. Ltd.

CytomX Therapeutics

0.8020
+0.04475.90%
Post-market: 0.82000.0180+2.24%19:38 EDT
Volume:1.42M
Turnover:1.13M
Market Cap:64.24M
PE:2.12
High:0.8250
Open:0.7700
Low:0.7602
Close:0.7573
Loading ...

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

Zacks
·
10 Jan

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Zacks
·
10 Jan

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

Zacks
·
09 Jan

FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

Zacks
·
09 Jan

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Zacks
·
08 Jan

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

Zacks
·
08 Jan

CytomX Therapeutics price target lowered to $5 from $8 at Wedbush

TIPRANKS
·
07 Jan

Wedbush Adjusts CytomX Therapeutics' PT to $5 From $8, Keeps Outperform Rating

MT Newswires Live
·
07 Jan

CytomX Therapeutics Inc : Wedbush Cuts Target Price to $5 From $8

THOMSON REUTERS
·
07 Jan

Piper Sandler Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)

TIPRANKS
·
07 Jan

H.C. Wainwright Keeps Their Hold Rating on CytomX Therapeutics (CTMX)

TIPRANKS
·
07 Jan

CytomX Therapeutics to Cut 40% of Workforce

Dow Jones
·
07 Jan

CytomX Therapeutics says focus on development of CRC treatment CX-2051 in FY25

TIPRANKS
·
07 Jan

CytomX Therapeutics Inc -CytomX Will Reduce Organizational Headcount by Approximately 40 Percent

THOMSON REUTERS
·
07 Jan

CytomX Therapeutics Inc - Initial Phase 1a Data for Cx-2051 Expected in H1 2025

THOMSON REUTERS
·
07 Jan

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

THOMSON REUTERS
·
07 Jan

CytomX Therapeutics Inc -Revised Focus and Associated Cost and Headcount Reductions Expected to Extend Cash Runway Into Q2 of 2026

THOMSON REUTERS
·
07 Jan

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Zacks
·
06 Jan

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Zacks
·
04 Jan

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Zacks
·
03 Jan